KPV 5 mg

DRAGON PHARMA KPV

Dragon Pharma presents KPV 5 mg, a premium research peptide containing the synthetic tripeptide Ac-KPV-NH2. This lyophilized powder represents a fragment of alpha-melanocyte-stimulating hormone (α-MSH) that has shown significant regulatory potential in experimental models investigating inflammatory pathways, immune modulation, and tissue integrity. As a research chemical, KPV offers scientists a focused tool to explore melanocortin receptor interactions and NF-κB pathway modulation without the complexity of full-length peptides.

DRUG COMPOSITION

Each 2 mL vial contains 5 mg of highly purified Ac-KPV-NH2 (Acetyl-Lysine-Proline-Valine-NH2) in lyophilized form. The product contains no additional active ingredients, binders, or preservatives that might interfere with experimental outcomes. Dragon Pharma's manufacturing process ensures batch-to-batch consistency with purity exceeding 99% as verified by HPLC analysis. The tripeptide sequence corresponds to residues 11-13 of α-MSH (Lys-Pro-Val), which research suggests contains the core anti-inflammatory signaling domain.

PHARMACEUTICAL FORM

KPV is supplied as a sterile lyophilized powder in a 2 mL glass vial sealed with a rubber stopper and aluminum crimp. The lyophilization process removes water while maintaining peptide stability, allowing for long-term storage without degradation. Researchers must reconstitute the powder with appropriate sterile solvents (typically bacteriostatic water or saline) based on their experimental protocols. The powder appears as a white to off-white crystalline substance that should dissolve completely in suitable solvents.

PHARMACEUTICAL GROUP AND ATC CODE

KPV belongs to the experimental peptide class with melanocortin receptor agonist properties. While not assigned a formal ATC code for therapeutic use, it falls under investigational agents affecting the immune and inflammatory systems. Research peptides like KPV are categorized as research chemicals for laboratory investigation rather than pharmaceuticals for human administration.

PHARMACOLOGICAL PROPERTIES

KPV exerts its research-observed effects through multiple mechanisms. Primarily, it acts as a ligand for melanocortin receptors (particularly MC1R and MC3R), which are expressed on various immune cells including macrophages and neutrophils. Activation of these receptors triggers intracellular signaling cascades that inhibit NF-κB nuclear translocation, thereby reducing expression of pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β. Studies published in journals like the Journal of Investigative Dermatology have documented that KPV's anti-inflammatory effects are concentration-dependent and comparable to full-length α-MSH in some experimental models.

Additionally, KPV appears to enhance epithelial barrier function by upregulating tight junction proteins and promoting wound healing responses. Unlike glucocorticoids, which broadly suppress immune function, KPV shows more selective modulation of inflammatory pathways while potentially preserving host defense mechanisms. Research indicates the peptide may also influence oxidative stress responses through modulation of antioxidant enzyme expression.

THERAPEUTICAL INDICATIONS

FOR RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. In experimental models, KPV has been investigated for potential applications in: (1) Inflammatory bowel disease models where epithelial barrier dysfunction and cytokine dysregulation are prominent; (2) Dermatological research involving cutaneous inflammation and barrier repair; (3) Studies examining mucosal immunity and gut-brain axis communication; (4) Models of systemic inflammatory responses and cytokine storm phenomena. The peptide's small size (molecular weight 370.5 Da) and stability profile make it suitable for various delivery method investigations.

DOSES AND METHOD OF ADMINISTRATION

RESEARCH APPLICATIONS ONLY. Experimental protocols vary significantly based on model systems. In published rodent studies, effective doses typically range from 50-500 μg/kg when administered systemically. For in vitro applications, concentrations from 10-100 μM are commonly tested. Researchers should establish appropriate dosing based on their specific experimental design, considering factors like administration route (systemic vs. local), duration of exposure, and biological endpoint measurements.

Reconstitution protocol: Using aseptic technique, add sterile bacteriostatic water or appropriate buffer to the vial. For a 5 mg vial, adding 1 mL yields a concentration of 5 mg/mL (5000 μg/mL). Further dilutions can be made according to experimental needs. The reconstituted solution should be clear and particle-free. Unused reconstituted material should be aliquoted and stored at -20°C to preserve stability.

CYCLE/STACKING

In research settings, KPV may be combined with other experimental compounds to investigate synergistic effects on inflammatory pathways, tissue repair, or metabolic processes. Researchers studying comprehensive recovery protocols might examine KPV alongside:

• BPC 157 - For comparative analysis of gastrointestinal protection and healing mechanisms
• TB-500/BPC-157 Combination - To study complementary effects on tissue repair and inflammation modulation
• GHK-Cu 50 mg - For research on combined antioxidant and anti-inflammatory effects in skin models
• SS-31 50 mg - To investigate mitochondrial protection alongside inflammatory pathway modulation
• DSIP 10 mg - For studies examining stress response systems and inflammatory cross-talk

Stacking strategies should be carefully designed with appropriate controls to distinguish individual compound effects from interactions. Researchers might administer compounds concurrently or sequentially based on their experimental hypotheses.

POST CYCLE THERAPY

As a research peptide with primarily anti-inflammatory mechanisms, KPV does not produce hormonal suppression that requires traditional post-cycle therapy. However, researchers should consider appropriate washout periods between experimental phases to avoid carryover effects. For studies combining KPV with compounds affecting endocrine axes, appropriate experimental design should include recovery observation periods and potential inclusion of compounds like Enclomiphene or Nolvadex in relevant control groups studying hormonal recovery.

SIDE EFFECTS

RESEARCH OBSERVATIONS ONLY. In experimental models, KPV has demonstrated an excellent safety profile with minimal observed adverse effects at research-relevant doses. Unlike glucocorticoids, it does not appear to cause immunosuppression leading to opportunistic infections in animal models. At extremely high doses (significantly above research recommendations), some studies noted transient reductions in normal inflammatory responses to pathogens. No hormonal side effects have been reported due to KPV's non-steroidal mechanism. Researchers should always follow appropriate safety protocols when handling any research chemicals.

CONTRAINDICATIONS

KPV is contraindicated for human consumption. For research purposes, experimental designs involving immunocompromised models or models with specific genetic alterations affecting melanocortin receptors should include additional controls. Researchers should avoid using KPV in studies where complete immunosuppression is required, as its modulatory rather than suppressive action might interfere with experimental outcomes.

OVERDOSE

In research settings, doses far exceeding typical experimental ranges (10-100 times research concentrations) have shown diminishing returns rather than acute toxicity in animal models. However, researchers should always adhere to established experimental protocols and consider dose-response relationships in their study design. No specific antidote exists for KPV overdose in research models; standard supportive measures appropriate to the experimental system should be employed if unexpected effects occur.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

KPV is for laboratory research use only by qualified professionals. Researchers should: (1) Use appropriate personal protective equipment when handling; (2) Maintain sterile technique during reconstitution to prevent contamination; (3) Store both lyophilized and reconstituted material at recommended temperatures; (4) Design experiments with appropriate controls to validate results; (5) Document all procedures and observations thoroughly; (6) Dispose of waste materials according to institutional guidelines for research chemicals. Cross-contamination with other peptides should be avoided through careful laboratory practices.

INTERACTIONS WITH OTHER DRUGS

In research models, KPV may interact with other compounds affecting inflammatory pathways. Concurrent administration with glucocorticoids might produce additive anti-inflammatory effects, while combination with immune stimulants could result in complex modulatory outcomes. Researchers investigating combination therapies should review literature on melanocortin receptor interactions with other signaling systems. A comprehensive review in Peptides Journal discusses potential interactions between melanocortin peptides and various pharmacological agents.

PRESENTATION, PACKAGING

Each package contains one 2 mL glass vial with 5 mg of Ac-KPV-NH2 as lyophilized powder. The vial is sealed with a bromobutyl rubber stopper and aluminum overseal to maintain sterility. Dragon Pharma packages each vial in individual protective boxes with temperature-stable inserts. Labels include product name, batch number, manufacturing date, expiration date (typically 24 months from manufacture when stored properly), and "For Research Use Only" designation. Larger research quantities may be available in multi-vial packs with additional documentation.

STORAGE

Store unopened vials at 2-8°C (refrigerated, not frozen) in original packaging protected from light. Under these conditions, lyophilized KPV remains stable for 24 months from manufacturing date. Avoid temperature fluctuations and exposure to humidity. After reconstitution, aliquoted solutions should be stored at -20°C and used within 30 days to prevent degradation. Repeated freeze-thaw cycles should be minimized. Always check reconstituted solutions for clarity and absence of particles before use in research.

DELIVERY TO THE USA

Dragon Pharma ships KPV 5 mg to research facilities in the United States through discrete packaging that maintains appropriate temperature conditions during transit. All packages are labeled for research use only and include documentation consistent with research chemical distribution. Domestic reshipping services ensure reliable delivery to all 50 states. Researchers should verify their institutional policies regarding receipt of research peptides before ordering. Delivery typically requires 7-14 business days depending on location and customs processing.

LEGAL STATUS

KPV is sold as a research chemical for laboratory investigation purposes only. It is not approved by the FDA for human use, diagnosis, or treatment of any condition. In the United States, possession and use of research peptides are legal for qualified researchers and institutions when used in accordance with applicable laws and regulations. Purchasers must be at least 18 years old and agree to use the product exclusively for research purposes in controlled laboratory settings. Researchers should comply with all institutional, state, and federal regulations governing research chemicals.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma, Europe

EXTERNAL LINKS

• PubChem Compound Summary for Ac-KPV-NH2 - Chemical properties and identifiers
• Journal of Investigative Dermatology: α-MSH peptides in inflammation - Research context for KPV mechanism

PROFILE

• Chemical name: Acetyl-Lysine-Proline-Valine-amide
• Chemical formula: C₁₉H₃₄N₆O₅
• Percentage of anabolic activity: Not applicable (non-hormonal peptide)
• Percentage of androgenic activity: 0% (no androgen receptor interaction)
• Active half life: Approximately 30-60 minutes in research models (route dependent)
• Recommended dosage: Research doses typically 50-500 μg/kg in animal models
• Acne: None reported in research
• Bloating (water retention): None reported in research
• HBR: No hepatobiliary effects reported
• Hepatic toxicity: None observed in research models
• Aromatization: Not applicable (non-steroidal compound)